BACKGROUND AND OBJECTIVES: The Dutch-Belgian HOVON group performed a randomized phase 3 trial to compare single non-myeloablative intensive treatment with double, intensive treatment in previously untreated patients with multiple myeloma (MM). DESIGN AND METHODS: Three hundred and three patients with stage II/III MM were randomized after VAD induction chemotherapy to receive two cycles of non-myeloablative intermediate-dose melphalan (70 mg/m2) (single treatment) or the same regimen followed by cyclophosphamide 120 mg/kg iv plus total body irradiation (TBI) 9 Gy and autologous stem cell transplantation (double, intensive treatment). In both treatment arms interferon .IIa was given as maintenance until relapse/progression. RESULTS: A significantly higher proportion of patients achieved a complete remission (CR) on protocol treatment with double, intensive therapy (32 % vs 13 %, p<0.001). Double treatment produced better outcome in terms of event-free survival (median 22 vs 21 months, 28% vs 14% at 4 years and 15% vs 7% at 6 years after randomization; logrank p=0.013; univariate HR 0.74, 95% CI, 0.58-0.94), progression-free survival (median 27 vs 24 months, 33% vs 16% at 4 years, and 17% vs 9% at 6 years after randomization; logrank p=0.006; HR=0.71, 95% CI 0.56-0.91), but not overall survival (median 50 vs 55 months, 52% vs 56% at 4 years and 39% vs 36% at 6 years after randomization; logrank p=0.51; HR=1.10, 95% CI 0.83-1.46). The achievement of a CR had a favorable prognostic impact on event-free survival (HR=0.60 , 95% CI=0.44 -0.82 , p=0.001) and progression-free survival (HR=0.62 , 95% CI=0.45 -0.84, p=0.002). INTERPRETATION AND CONCLUSIONS: Double, intensive treatment resulted in a better CR rate, event-free survival and progression-free survival but not overall survival compared to single non-myeloablative treatment in previously untreated patients with multiple myeloma.
RCT Entities:
BACKGROUND AND OBJECTIVES: The Dutch-Belgian HOVON group performed a randomized phase 3 trial to compare single non-myeloablative intensive treatment with double, intensive treatment in previously untreated patients with multiple myeloma (MM). DESIGN AND METHODS: Three hundred and three patients with stage II/III MM were randomized after VAD induction chemotherapy to receive two cycles of non-myeloablative intermediate-dose melphalan (70 mg/m2) (single treatment) or the same regimen followed by cyclophosphamide 120 mg/kg iv plus total body irradiation (TBI) 9 Gy and autologous stem cell transplantation (double, intensive treatment). In both treatment arms interferon .IIa was given as maintenance until relapse/progression. RESULTS: A significantly higher proportion of patients achieved a complete remission (CR) on protocol treatment with double, intensive therapy (32 % vs 13 %, p<0.001). Double treatment produced better outcome in terms of event-free survival (median 22 vs 21 months, 28% vs 14% at 4 years and 15% vs 7% at 6 years after randomization; logrank p=0.013; univariate HR 0.74, 95% CI, 0.58-0.94), progression-free survival (median 27 vs 24 months, 33% vs 16% at 4 years, and 17% vs 9% at 6 years after randomization; logrank p=0.006; HR=0.71, 95% CI 0.56-0.91), but not overall survival (median 50 vs 55 months, 52% vs 56% at 4 years and 39% vs 36% at 6 years after randomization; logrank p=0.51; HR=1.10, 95% CI 0.83-1.46). The achievement of a CR had a favorable prognostic impact on event-free survival (HR=0.60 , 95% CI=0.44 -0.82 , p=0.001) and progression-free survival (HR=0.62 , 95% CI=0.45 -0.84, p=0.002). INTERPRETATION AND CONCLUSIONS: Double, intensive treatment resulted in a better CR rate, event-free survival and progression-free survival but not overall survival compared to single non-myeloablative treatment in previously untreated patients with multiple myeloma.
Authors: Sergio Giralt; David H Vesole; George Somlo; Amrita Krishnan; Edward Stadtmauer; Philip Mccarthy; Marcelo C Pasquini Journal: J Natl Cancer Inst Date: 2009-06-17 Impact factor: 13.506
Authors: Laura C Michaelis; Ayman Saad; Xiaobo Zhong; Jennifer Le-Rademacher; Cesar O Freytes; David I Marks; Hillard M Lazarus; Jennifer M Bird; Leona Holmberg; Rammurti T Kamble; Shaji Kumar; Michael Lill; Kenneth R Meehan; Wael Saber; Jeffrey Schriber; Jason Tay; Dan T Vogl; Baldeep Wirk; Bipin N Savani; Robert P Gale; David H Vesole; Gary J Schiller; Muneer Abidi; Kenneth C Anderson; Taiga Nishihori; Matt E Kalaycio; Julie M Vose; Jan S Moreb; William Drobyski; Reinhold Munker; Vivek Roy; Armin Ghobadi; H Kent Holland; Rajneesh Nath; L Bik To; Angelo Maiolino; Adetola A Kassim; Sergio A Giralt; Heather Landau; Harry C Schouten; Richard T Maziarz; Joseph Mikhael; Tamila Kindwall-Keller; Patrick J Stiff; John Gibson; Sagar Lonial; Amrita Krishnan; Angela Dispenzieri; Parameswaran Hari Journal: Biol Blood Marrow Transplant Date: 2013-01-05 Impact factor: 5.742
Authors: Ali Agool; Riemer H J A Slart; Rudi A J O Dierckx; Philip M Kluin; Lydia Visser; Pieter L Jager; Edo Vellenga Journal: Eur J Nucl Med Mol Imaging Date: 2010-01 Impact factor: 9.236
Authors: H Goldschmidt; H M Lokhorst; E K Mai; B van der Holt; I W Blau; S Zweegman; K C Weisel; E Vellenga; M Pfreundschuh; M J Kersten; C Scheid; S Croockewit; R Raymakers; D Hose; A Potamianou; A Jauch; J Hillengass; M Stevens-Kroef; M S Raab; A Broijl; H W Lindemann; G M J Bos; P Brossart; M van Marwijk Kooy; P Ypma; U Duehrsen; R M Schaafsma; U Bertsch; T Hielscher; Le Jarari; H J Salwender; P Sonneveld Journal: Leukemia Date: 2017-07-04 Impact factor: 11.528